Buda J A, Suciu-Foca N, Blomain E, McManus S, Reemtsma K
J Surg Oncol. 1975;7(6):525-9. doi: 10.1002/jso.2930070613.
The ability of peripheral blood lymphocytes to respond in vitro to phytohemagglutinin (PHA) and to allogeneic cells in mixed leukocyte reaction (MLC) was studied in 85 patients with cancer and in 50 healthy controls. The effect produced by sera from cancer patients on in vitro lymphocyte blastogenesis was tested on autologous cells and on homologous cells from a constant panel of 10 normal volunteers. Patients with cancer showed a distinct deficiency of cellular immune responsiveness reflected in a stage-related impairment of PHA and MLC reactivity. This deficiency seems at least partially attributable to the presence of lymphocyte depressive factors in cancer sera, since such sera reduced the reactivity of both autologous and normal homologous lymphocytes to a level that was significantly lower than that found in the presence of pooled normal serum. The inhibitory activity of cancer sera was directly related to the extent of the neoplasia.
在85例癌症患者和50名健康对照者中，研究了外周血淋巴细胞在体外对植物血凝素（PHA）的反应能力以及在混合淋巴细胞反应（MLC）中对同种异体细胞的反应能力。检测了癌症患者血清对体外淋巴细胞增殖的影响，所用细胞为自体细胞以及来自10名固定正常志愿者的同源细胞。癌症患者表现出明显的细胞免疫反应缺陷，表现为PHA和MLC反应性与分期相关的损害。这种缺陷似乎至少部分归因于癌症血清中存在淋巴细胞抑制因子，因为此类血清可将自体和正常同源淋巴细胞的反应性降低至显著低于存在混合正常血清时的水平。癌症血清的抑制活性与肿瘤形成的程度直接相关。
